Braveheart Bio raised about $382 million in an IPO, pushing total proceeds to nearly $440 million after underwriters exercised an option to buy additional shares. The company’s lead heart drug targets a type of cardiomyopathy and is positioned as potentially competitive with a Bristol Myers Squibb medicine. The listing highlights investor appetite for clinical-stage cardiovascular development, particularly where the pipeline could address major treatment gaps. The scale of the offering also suggests confidence in the program’s near- to mid-term development path. Braveheart’s IPO timing contributed to a busy week for biotech public financings, with the deal described as the biggest biotech IPO of the week.